Exicure Inc (XCUR) USD0.0001

Sell:$3.56Buy:$4.26Price increased$0.16 (4.01%)

Prices delayed by at least 15 minutes
Sell:$3.56
Buy:$4.26
Change:Price increased$0.16 (4.01%)
Deal now
Prices delayed by at least 15 minutes
Sell:$3.56
Buy:$4.26
Change:Price increased$0.16 (4.01%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Key people

Jung Soo Kim
President, Chief Executive Officer, Director
Gyuyeob Lee
Chief Financial Officer, Company Secretary
Josephine Cardarelli
Chief Scientific Officer
Gyeung Seog Cheon
Director
Jung Kyu Ham
Director
Dongho Lee
Independent Director
Sangjn Yeo
Independent Director
Click to see more

Key facts

  • Shares in issue
    6.37m
  • EPIC
    XCUR
  • ISIN
    US30205M3097
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $22.75m
  • Employees
    8
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.